KoBioLabs, Inc. Logo

KoBioLabs, Inc.

Develops microbiome-based therapeutics for immune, metabolic, and brain disorders.

348150 | KO

Overview

Corporate Details

ISIN(s):
KR7348150004
LEI:
Country:
South Korea
Address:
서울특별시 관악구 관악로 1 220동 745-1호(신림동, 서울대학교종합연구동), 서울특별시

Description

KoBioLabs, Inc. is a biotechnology company that develops innovative microbiome-based therapeutics. The company utilizes its proprietary Smartiome® platform, an integrated system for discovering novel drug candidates that employs AI-driven multi-omics analysis and a comprehensive microbiome library with a reverse-translation approach. KoBioLabs is focused on creating a pipeline of new drugs to treat a range of immune, metabolic, and brain disorders. The company also applies advanced technologies, including a microbe-based drug delivery system (mDDS) and biofoundry techniques, to enhance the efficacy of its treatments and address unmet medical needs.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-08-14 00:00
반기보고서 (2025.06)
Korean 1.5 MB
2025-05-15 00:00
분기보고서 (2025.03)
Korean 1.1 MB
2025-03-31 00:00
정기주주총회결과
Korean 28.2 KB
2025-03-31 00:00
사외이사의선임ㆍ해임또는중도퇴임에관한신고
Korean 11.3 KB
2025-03-31 00:00
[기재정정]사외이사의선임ㆍ해임또는중도퇴임에관한신고
Korean 14.1 KB
2025-03-20 00:00
사업보고서 (2024.12)
Korean 483.3 KB
2025-03-20 00:00
감사보고서제출
Korean 26.0 KB
2025-03-14 00:00
주주총회소집공고
Korean 225.0 KB
2025-03-06 00:00
주주총회소집결의
Korean 17.6 KB
2025-02-14 00:00
매출액또는손익구조30%(대규모법인은15%)이상변동
Korean 11.2 KB
2024-12-13 00:00
주주명부폐쇄기간또는기준일설정
Korean 4.3 KB
2024-11-14 00:00
[기재정정]사업보고서 (2023.12)
Korean 1.8 MB
2024-11-14 00:00
[기재정정]분기보고서 (2024.03)
Korean 1.1 MB
2024-11-14 00:00
[기재정정]반기보고서 (2024.06)
Korean 1.5 MB
2024-11-14 00:00
분기보고서 (2024.09)
Korean 1.2 MB

Automate Your Workflow. Get a real-time feed of all KoBioLabs, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for KoBioLabs, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for KoBioLabs, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

4BASEBIO PLC Logo
Manufactures GMP-grade synthetic DNA for next-generation therapeutics and vaccines.
United Kingdom
4BB
4D Molecular Therapeutics, Inc. Logo
Develops genetic medicines using AAV vectors for ophthalmology and pulmonology diseases.
United States of America
FDMT
4SC AG Logo
Biopharmaceutical company with no products under development or operational business.
Germany
VSC
60 DEGREES PHARMACEUTICALS, INC. Logo
Develops and commercializes medicines for infectious diseases, focusing on tropical illnesses.
United States of America
SXTP
89bio, Inc. Logo
Clinical-stage biopharma developing therapies for liver and cardiometabolic diseases.
United States of America
ETNB
Aardvark Therapeutics, Inc. Logo
Clinical-stage biopharma developing therapeutics for hunger and metabolic diseases.
United States of America
AARD
ABBOTT LABORATORIES Logo
Global healthcare company in medical devices, diagnostics, nutrition & pharmaceuticals.
United States of America
ABT
AbbVie Inc. Logo
A research-based biopharmaceutical company developing and manufacturing medicines.
United States of America
ABBV
AbCellera Biologics Inc. Logo
Discovers and develops antibody-based therapeutics using a proprietary platform.
United States of America
ABCL
Develops antibody-based therapeutics using CAR-T, NEST, and AffiMab platforms.
South Korea
174900

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.